QR-Code

Open-label phase I clinical trial of Ad5-EBOV in Africans in China

Background: To determine the safety and immunogenicity of a novel recombinant adenovirus type 5 vector based Ebola virus disease vaccine (Ad5-EBOV) in Africans in China. Methods: A phase 1, dose-escalation, open-label trial was conducted. 61 healthy Africans were sequentially enrolled, with 31 parti...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Lihua Wu, Zhe Zhang, Hainv Gao, Yuhua Li, Lihua Hou, Hangping Yao, Shipo Wu, Jian Liu, Ling Wang, You Zhai, Huilin Ou, Meihua Lin, Xiaoxin Wu, Jingjing Liu, Guanjing Lang, Qian Xin, Guolan Wu, Li Luo, Pei Liu, Jianzhong Shentu, Nanping Wu, Jifang Sheng, Yunqing Qiu, Wei Chen, Lanjuan Li
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis Group 2017-09-01
Schriftenreihe:Human Vaccines & Immunotherapeutics
Schlagworte:
ad5-ebov
gp antibody
immunogenicity
safety
t-cell response
Online-Zugang:http://dx.doi.org/10.1080/21645515.2017.1342021
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge